loratadine has been researched along with Nasal Obstruction in 29 studies
Loratadine: A second-generation histamine H1 receptor antagonist used in the treatment of allergic rhinitis and urticaria. Unlike most classical antihistamines (HISTAMINE H1 ANTAGONISTS) it lacks central nervous system depressing effects such as drowsiness.
loratadine : A benzocycloheptapyridine that is 6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine substituted by a chloro group at position 8 and a 1-(ethoxycarbonyl)piperidin-4-ylidene group at position 11. It is a H1-receptor antagonist commonly employed in the treatment of allergic disorders.
Nasal Obstruction: Any hindrance to the passage of air into and out of the nose. The obstruction may be unilateral or bilateral, and may involve any part of the NASAL CAVITY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Desloratadine-montelukast combination therapy causes subjective and objective decrease in nasal obstruction, reduces the other symptoms of PAR and improves the disease-specific QoL." | 9.17 | Desloratadine-montelukast combination improves quality of life and decreases nasal obstruction in patients with perennial allergic rhinitis. ( Cingi, C; Erdogmus, N; Eskiizmir, G; Oghan, F; Ural, A; Yaz, A, 2013) |
| "When compared with desloratadine and placebo, Ze 339 shows better efficacy in relieving nasal obstruction symptoms and inhibiting critical components of the chemokine network and as such represents a novel symptomatic and possible prophylactic treatment for allergic rhinitis." | 9.15 | Petasol butenoate complex (Ze 339) relieves allergic rhinitis-induced nasal obstruction more effectively than desloratadine. ( Chaker, AM; Dumitru, AF; Greve, J; Hess, L; Hindersin, S; Klenzner, T; Nebel, S; Scheckenbach, K; Schmidt-Weber, CB; Shamji, M; Wagenmann, M; Zahner, C; Zimmermann, C, 2011) |
| "Nasal obstruction, as measured by nasal airflow, was less severe with desloratadine than with placebo (P <." | 9.10 | Effect of desloratadine versus placebo on nasal airflow and subjective measures of nasal obstruction in subjects with grass pollen-induced allergic rhinitis in an allergen-exposure unit. ( Harris, AG; Horak, F; Stübner, UP; Zieglmayer, R, 2002) |
| " Desloratadine therapy significantly reduced nasal and ocular symptom severity, itching and wheals, and sleep and activity disruption (p < 0." | 8.86 | Safety and efficacy of desloratadine in subjects with seasonal allergic rhinitis or chronic urticaria: results of four postmarketing surveillance studies. ( Bachert, C; Maurer, M, 2010) |
| "The objective of the study is to assess the efficacy of the nonsedating antihistamine, desloratadine, in the treatment of allergic rhinitis (AR)." | 8.84 | Efficacy of desloratadine in the treatment of allergic rhinitis: a meta-analysis of randomized, double-blind, controlled trials. ( Canonica, GW; Compalati, E; Penagos, M; Tarantini, F, 2007) |
| "Levocetirizine treatment induced significant symptom relief (P=0." | 6.71 | Levocetirizine improves nasal obstruction and modulates cytokine pattern in patients with seasonal allergic rhinitis: a pilot study. ( Ciprandi, G; Cirillo, I; Tosca, MA; Vizzaccaro, A, 2004) |
| "Nasal obstruction is the main symptom in patients with perennial allergic rhinitis." | 6.71 | Desloratadine and levocetirizine improve nasal symptoms, airflow, and allergic inflammation in patients with perennial allergic rhinitis: a pilot study. ( Allen, M; Barberi, S; Ciprandi, G; Cirillo, I; Civardi, E; Marseglia, GL; Vizzaccaro, A, 2005) |
| "Desloratadine-montelukast combination therapy causes subjective and objective decrease in nasal obstruction, reduces the other symptoms of PAR and improves the disease-specific QoL." | 5.17 | Desloratadine-montelukast combination improves quality of life and decreases nasal obstruction in patients with perennial allergic rhinitis. ( Cingi, C; Erdogmus, N; Eskiizmir, G; Oghan, F; Ural, A; Yaz, A, 2013) |
| "When compared with desloratadine and placebo, Ze 339 shows better efficacy in relieving nasal obstruction symptoms and inhibiting critical components of the chemokine network and as such represents a novel symptomatic and possible prophylactic treatment for allergic rhinitis." | 5.15 | Petasol butenoate complex (Ze 339) relieves allergic rhinitis-induced nasal obstruction more effectively than desloratadine. ( Chaker, AM; Dumitru, AF; Greve, J; Hess, L; Hindersin, S; Klenzner, T; Nebel, S; Scheckenbach, K; Schmidt-Weber, CB; Shamji, M; Wagenmann, M; Zahner, C; Zimmermann, C, 2011) |
| "Nasal obstruction, as measured by nasal airflow, was less severe with desloratadine than with placebo (P <." | 5.10 | Effect of desloratadine versus placebo on nasal airflow and subjective measures of nasal obstruction in subjects with grass pollen-induced allergic rhinitis in an allergen-exposure unit. ( Harris, AG; Horak, F; Stübner, UP; Zieglmayer, R, 2002) |
| " Desloratadine therapy significantly reduced nasal and ocular symptom severity, itching and wheals, and sleep and activity disruption (p < 0." | 4.86 | Safety and efficacy of desloratadine in subjects with seasonal allergic rhinitis or chronic urticaria: results of four postmarketing surveillance studies. ( Bachert, C; Maurer, M, 2010) |
| "The objective of the study is to assess the efficacy of the nonsedating antihistamine, desloratadine, in the treatment of allergic rhinitis (AR)." | 4.84 | Efficacy of desloratadine in the treatment of allergic rhinitis: a meta-analysis of randomized, double-blind, controlled trials. ( Canonica, GW; Compalati, E; Penagos, M; Tarantini, F, 2007) |
| "Desloratadine treatment for 14 days improved nasal airflow and resistance as well as symptom and QOL scores in patients with symptomatic SAR during the allergy season." | 2.72 | Effect of desloratadine therapy on symptom scores and measures of nasal patency in seasonal allergic rhinitis: results of a single-center, placebo-controlled trial. ( Harris, AG; Iezzoni, D; Jalowayski, AA; Meltzer, EO; Vogt, K, 2006) |
| "Montelukast is a leukotriene receptor antagonist recently approved for the treatment of seasonal allergic rhinitis (SAR)." | 2.71 | Fluticasone propionate aqueous nasal spray provided significantly greater improvement in daytime and nighttime nasal symptoms of seasonal allergic rhinitis compared with montelukast. ( Arastu, R; Baidoo, CA; Faris, MA; Howland, WC; Klein, KC; Philpot, EE; Ratner, PH; Rickard, KA, 2003) |
| "Levocetirizine treatment induced significant symptom relief (P=0." | 2.71 | Levocetirizine improves nasal obstruction and modulates cytokine pattern in patients with seasonal allergic rhinitis: a pilot study. ( Ciprandi, G; Cirillo, I; Tosca, MA; Vizzaccaro, A, 2004) |
| " No unusual or unexpected adverse events were reported." | 2.71 | Efficacy and safety of an extended-release formulation of desloratadine and pseudoephedrine vs the individual components in the treatment of seasonal allergic rhinitis. ( Grubbe, R; Lutsky, B; Pleskow, W; Weiss, S, 2005) |
| "Nasal obstruction is the main symptom in patients with perennial allergic rhinitis." | 2.71 | Desloratadine and levocetirizine improve nasal symptoms, airflow, and allergic inflammation in patients with perennial allergic rhinitis: a pilot study. ( Allen, M; Barberi, S; Ciprandi, G; Cirillo, I; Civardi, E; Marseglia, GL; Vizzaccaro, A, 2005) |
| "Desloratadine is a new treatment option for patients with IAR and nasal congestion." | 2.70 | Desloratadine reduces nasal congestion in patients with intermittent allergic rhinitis. ( Nayak, AS; Schenkel, E, 2001) |
| " Recommended dosage of loratadine (CAS 79794-75-5) is 10 mg once daily, whereas terfenadine (CAS 50679-08-8) until recently has been recommended as 60 mg twice daily." | 2.67 | Comparison of loratadine and terfenadine in allergic seasonal rhinoconjunctivitis with emphasis on nasal stuffiness and peak flow. ( Hindberg Rasmussen, W; Høi, L; Lorentzen, KA; Nüchel Petersen, L; Olsen, OT; Svendsen, UG, 1992) |
| " Mean reductions in nasal congestion scores were comparable between the once- and twice-daily dosing regimens of the combination drug." | 2.45 | Desloratadine and pseudoephedrine combination therapy as a comprehensive treatment for allergic rhinitis and nasal congestion. ( Anolik, R, 2009) |
| "Fexofenadine was associated with significantly lower nasal congestion scores compared with placebo in 4 studies (P <- 0." | 2.45 | A review of the efficacy of desloratadine, fexofenadine, and levocetirizine in the treatment of nasal congestion in patients with allergic rhinitis. ( Bachert, C, 2009) |
| "Desloratadine treatment was associated with less deterioration from baseline in the mean nasal airflow (P < 0." | 2.41 | Impact and modulation of nasal obstruction. ( Horak, F, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.45) | 18.2507 |
| 2000's | 22 (75.86) | 29.6817 |
| 2010's | 5 (17.24) | 24.3611 |
| 2020's | 1 (3.45) | 2.80 |
| Authors | Studies |
|---|---|
| Zhao, J | 1 |
| Yan, X | 1 |
| Gai, J | 1 |
| Han, J | 1 |
| Zhang, H | 1 |
| Luo, H | 1 |
| Huang, S | 1 |
| Wang, J | 1 |
| Liu, X | 2 |
| Ren, Y | 1 |
| Yang, H | 1 |
| Sun, X | 1 |
| Huang, H | 1 |
| Cingi, C | 1 |
| Oghan, F | 1 |
| Eskiizmir, G | 1 |
| Yaz, A | 1 |
| Ural, A | 1 |
| Erdogmus, N | 1 |
| Anolik, R | 2 |
| Grubbe, RE | 1 |
| Lumry, WR | 1 |
| Bachert, C | 2 |
| Holmberg, K | 1 |
| Tonnel, AB | 1 |
| Dreyfus, I | 2 |
| Olsson, P | 1 |
| Cougnard, J | 1 |
| Mesbah, K | 2 |
| Devillier, P | 1 |
| Demoly, P | 1 |
| Dhivert-Donnadieu, H | 1 |
| Maurer, M | 1 |
| Dumitru, AF | 1 |
| Shamji, M | 1 |
| Wagenmann, M | 1 |
| Hindersin, S | 1 |
| Scheckenbach, K | 1 |
| Greve, J | 1 |
| Klenzner, T | 1 |
| Hess, L | 1 |
| Nebel, S | 1 |
| Zimmermann, C | 1 |
| Zahner, C | 1 |
| Schmidt-Weber, CB | 1 |
| Chaker, AM | 1 |
| Karaki, M | 1 |
| Akiyama, K | 1 |
| Mori, N | 1 |
| Horak, F | 2 |
| Van Cauwenberge, P | 1 |
| Ratner, P | 1 |
| Hampel, F | 1 |
| Gispert, J | 1 |
| Ratner, PH | 1 |
| Howland, WC | 1 |
| Arastu, R | 1 |
| Philpot, EE | 1 |
| Klein, KC | 1 |
| Baidoo, CA | 1 |
| Faris, MA | 1 |
| Rickard, KA | 1 |
| Ciprandi, G | 2 |
| Cirillo, I | 2 |
| Vizzaccaro, A | 2 |
| Tosca, MA | 1 |
| Lee, DK | 1 |
| Currie, GP | 1 |
| Pleskow, W | 1 |
| Grubbe, R | 1 |
| Weiss, S | 1 |
| Lutsky, B | 1 |
| Civardi, E | 1 |
| Barberi, S | 1 |
| Allen, M | 1 |
| Marseglia, GL | 1 |
| Meltzer, EO | 1 |
| Jalowayski, AA | 1 |
| Vogt, K | 1 |
| Iezzoni, D | 1 |
| Harris, AG | 2 |
| Raphael, GD | 1 |
| Angello, JT | 1 |
| Wu, MM | 1 |
| Druce, HM | 1 |
| Canonica, GW | 1 |
| Tarantini, F | 1 |
| Compalati, E | 1 |
| Penagos, M | 1 |
| Buczyłko, K | 1 |
| Chwała, C | 1 |
| Zielińska-Bliźniewska, H | 1 |
| Wagner, A | 1 |
| Dzwonnik, A | 1 |
| Nayak, AS | 1 |
| Schenkel, E | 1 |
| Stübner, UP | 1 |
| Zieglmayer, R | 1 |
| Olsen, OT | 1 |
| Nüchel Petersen, L | 1 |
| Høi, L | 1 |
| Lorentzen, KA | 1 |
| Hindberg Rasmussen, W | 1 |
| Svendsen, UG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multi-Centre, Double-Blind, Randomised Comparison Of The Effects Of Desloratadine (Aerius®) And Placebo In The Relief Of Nasal Symptom Scores In Subjects With Seasonal Allergic Rhinitis (Sar) To Cypress Pollen[NCT00867191] | Phase 4 | 233 participants (Actual) | Interventional | 2002-02-01 | Completed | ||
| Aprepitant vs. Desloratadine in Non-small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Related Pruritus: A Prospective, Randomized Control, Double-blinded, Phase II Clinical Trial[NCT02646020] | Phase 2 | 138 participants (Actual) | Interventional | 2015-12-31 | Completed | ||
| The Addition of Montelukast to Fluticasone in the Treatment of Perennial Allergic Rhinitis[NCT00119015] | Phase 4 | 102 participants (Actual) | Interventional | 2005-07-31 | Terminated (stopped due to Difficulty in recruitment) | ||
| Effectiveness of Montelukast Versus Intranasal Fluticasone Propionate in the Management of Allergic Rhinitis Among Children 02 to 05 Years of Age[NCT04957927] | Phase 4 | 60 participants (Anticipated) | Interventional | 2020-12-12 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Patients recorded the severity of other symptoms, including itchy nose/eyes and post-nasal drip, twice a day on a scale from 0 to 3 (0 = no symptoms, 1 = mild, 2 = moderate, and 3 = severe). The other symptom score was calculated as the sum of all scores for morning and evening recordings with a range of 0 to 6.~The baseline symptom score used in the analysis was the average of the symptom scores from the last 5 days of fluticasone propionate therapy prior to randomized treatment period.~The change from baseline for each subsequent day of treatment was then calculated for each subject. So that each subject only had one observation, the average of these changes was calculated for each subject, and this summary measure was used in the analysis comparing the two treatment groups. We report the median and full range of these average changes for each group.~A negative value indicates an improvement in symptoms." (NCT00119015)
Timeframe: Baseline and 2 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Fluticasone Propionate + Montelukast | -0.24 |
| Fluticasone Propionate + Placebo | -0.14 |
"Patients recorded the severity of runny nose twice a day on a scale from 0 to 3 (0 = no symptoms, 1 = mild, 2 = moderate, and 3 = severe). The runny nose symptom score was calculated as the sum of all scores for morning and evening recordings with a range of 0 to 6.~The baseline symptom score used in the analysis was the average of the symptom scores from the last 5 days of fluticasone propionate therapy prior to randomized treatment period.~The change from baseline for each subsequent day of treatment was then calculated for each subject. So that each subject only had one observation, the average of these changes was calculated for each subject, and this summary measure was used in the analysis comparing the two treatment groups. We report the median and full range of these average changes for each group.~A negative value indicates an improvement in symptoms." (NCT00119015)
Timeframe: Baseline and 2 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Fluticasone Propionate + Montelukast | -0.52 |
| Fluticasone Propionate + Placebo | -0.29 |
"Patients recorded the severity of sneezing twice a day on a scale from 0 to 3 (0 = no symptoms, 1 = mild, 2 = moderate, and 3 = severe). The sneezing symptom score was calculated as the sum of all scores for morning and evening recordings with a range of 0 to 6.~The baseline symptom score used in the analysis was the average of the symptom scores from the last 5 days of fluticasone propionate therapy prior to randomized treatment period.~The change from baseline for each subsequent day of treatment was then calculated for each subject. So that each subject only had one observation, the average of these changes was calculated for each subject, and this summary measure was used in the analysis comparing the two treatment groups. We report the median and full range of these average changes for each group.~A negative value indicates an improvement in symptoms." (NCT00119015)
Timeframe: Baseline and 2 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Fluticasone Propionate + Montelukast | -0.22 |
| Fluticasone Propionate + Placebo | -0.25 |
"Patients recorded the severity of stuffy nose twice a day on a scale from 0 to 3 (0 = no symptoms, 1 = mild, 2 = moderate, and 3 = severe). The stuffy nose symptom score was calculated as the sum of all scores for morning and evening recordings with a range of 0 to 6.~The baseline symptom score used in the analysis was the average of the symptom scores from the last 5 days of fluticasone propionate therapy prior to randomized treatment period.~The change from baseline for each subsequent day of treatment was then calculated for each subject. So that each subject only had one observation, the average of these changes was calculated for each subject, and this summary measure was used in the analysis comparing the two treatment groups. We report the median and full range of these average changes for each group.~A negative value indicates an improvement in symptoms." (NCT00119015)
Timeframe: Baseline and 2 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Fluticasone Propionate + Montelukast | -0.41 |
| Fluticasone Propionate + Placebo | -0.47 |
"Patients recorded the severity of sneezing, runny nose, stuffy nose, and other symptoms (itchy nose/eyes and post-nasal drip) twice a day on a scale from 0 to 3 (0 = no symptoms, 1 = mild, 2 = moderate, and 3 = severe). The TNSS was calculated as the sum of all scores for morning and evening recordings with a range of 0 to 24.~The baseline TNSS used in the analysis was the average of the symptom scores from the last 5 days of fluticasone propionate therapy prior to randomized treatment period.~The change from baseline for each subsequent day of treatment was then calculated for each subject. So that each subject only had one observation, the average of these changes was calculated for each subject, and this summary measure was used in the analysis comparing the two treatment groups. We report the median and full range of these average changes for each group.~A negative value indicates an improvement in symptoms." (NCT00119015)
Timeframe: Baseline and 2 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Fluticasone Propionate + Montelukast | -1.66 |
| Fluticasone Propionate + Placebo | -2.21 |
6 reviews available for loratadine and Nasal Obstruction
| Article | Year |
|---|---|
Desloratadine and pseudoephedrine combination therapy as a comprehensive treatment for allergic rhinitis and nasal congestion.
Topics: Clinical Trials as Topic; Drug Combinations; Histamine H1 Antagonists, Non-Sedating; Humans; Loratad | 2009 |
A review of the efficacy of desloratadine, fexofenadine, and levocetirizine in the treatment of nasal congestion in patients with allergic rhinitis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cetirizine; Child; Clinical Trials as Topic; Female; His | 2009 |
Safety and efficacy of desloratadine in subjects with seasonal allergic rhinitis or chronic urticaria: results of four postmarketing surveillance studies.
Topics: Activities of Daily Living; Adult; Anti-Allergic Agents; Chronic Disease; Female; Germany; Histamine | 2010 |
Impact and modulation of nasal obstruction.
Topics: Histamine H1 Antagonists; Humans; Loratadine; Nasal Obstruction; Randomized Controlled Trials as Top | 2002 |
Advances in allergy management.
Topics: Histamine H1 Antagonists; Humans; Inflammation Mediators; Loratadine; Nasal Obstruction; Quality of | 2002 |
Efficacy of desloratadine in the treatment of allergic rhinitis: a meta-analysis of randomized, double-blind, controlled trials.
Topics: Double-Blind Method; Histamine H1 Antagonists, Non-Sedating; Humans; Hypersensitivity; Loratadine; N | 2007 |
18 trials available for loratadine and Nasal Obstruction
| Article | Year |
|---|---|
Efficacy of Bimin decoction for patients with perennial allergic rhinitis: an open-label non-inferiority randomized controlled trial.
Topics: Adult; Anti-Allergic Agents; Drugs, Chinese Herbal; Female; Fluticasone; Humans; Loratadine; Male; M | 2019 |
Clinical Efficacy of Vitamin D3 Adjuvant Therapy in Allergic Rhinitis: A Randomized Controlled Trial.
Topics: Adjuvants, Pharmaceutic; Adolescent; Adult; Cholecalciferol; Drug Therapy, Combination; Eosinophils; | 2020 |
Desloratadine-montelukast combination improves quality of life and decreases nasal obstruction in patients with perennial allergic rhinitis.
Topics: Acetates; Adult; Cyclopropanes; Drug Combinations; Female; Humans; Leukotriene Antagonists; Loratadi | 2013 |
Efficacy and safety of desloratadine/pseudoephedrine combination vs its components in seasonal allergic rhinitis.
Topics: Adolescent; Adult; Aged; Bronchodilator Agents; Child; Double-Blind Method; Drug Synergism; Drug The | 2009 |
Desloratadine relieves nasal congestion and improves quality-of-life in persistent allergic rhinitis.
Topics: Adult; Double-Blind Method; Female; Histamine H1 Antagonists, Non-Sedating; Humans; Loratadine; Male | 2009 |
Desloratadine for the treatment of cypress pollen-induced allergic rhinitis.
Topics: Adult; Antigens, Plant; Cupressus; Disease Progression; Double-Blind Method; Female; France; Histami | 2009 |
Petasol butenoate complex (Ze 339) relieves allergic rhinitis-induced nasal obstruction more effectively than desloratadine.
Topics: Adult; Allergens; Anti-Allergic Agents; Bronchial Provocation Tests; Chemokines; Cross-Over Studies; | 2011 |
Efficacy of intranasal steroid spray (mometasone furoate) on treatment of patients with seasonal allergic rhinitis: comparison with oral corticosteroids.
Topics: Administration, Intranasal; Administration, Oral; Adult; Aged; Anti-Allergic Agents; Betamethasone; | 2013 |
Efficacy of ebastine in the control of nasal congestion associated with allergic rhinitis.
Topics: Adult; Ambrosia; Butyrophenones; Dose-Response Relationship, Drug; Double-Blind Method; Female; Hist | 2003 |
Fluticasone propionate aqueous nasal spray provided significantly greater improvement in daytime and nighttime nasal symptoms of seasonal allergic rhinitis compared with montelukast.
Topics: Acetates; Administration, Intranasal; Administration, Oral; Adult; Androstadienes; Anti-Allergic Age | 2003 |
Fluticasone propionate aqueous nasal spray provided significantly greater improvement in daytime and nighttime nasal symptoms of seasonal allergic rhinitis compared with montelukast.
Topics: Acetates; Administration, Intranasal; Administration, Oral; Adult; Androstadienes; Anti-Allergic Age | 2003 |
Fluticasone propionate aqueous nasal spray provided significantly greater improvement in daytime and nighttime nasal symptoms of seasonal allergic rhinitis compared with montelukast.
Topics: Acetates; Administration, Intranasal; Administration, Oral; Adult; Androstadienes; Anti-Allergic Age | 2003 |
Fluticasone propionate aqueous nasal spray provided significantly greater improvement in daytime and nighttime nasal symptoms of seasonal allergic rhinitis compared with montelukast.
Topics: Acetates; Administration, Intranasal; Administration, Oral; Adult; Androstadienes; Anti-Allergic Age | 2003 |
Levocetirizine improves nasal obstruction and modulates cytokine pattern in patients with seasonal allergic rhinitis: a pilot study.
Topics: Adult; Cetirizine; Double-Blind Method; Eosinophils; Female; Histamine H1 Antagonists; Humans; Inter | 2004 |
Efficacy and safety of an extended-release formulation of desloratadine and pseudoephedrine vs the individual components in the treatment of seasonal allergic rhinitis.
Topics: Adolescent; Adult; Aged; Child; Double-Blind Method; Drug Combinations; Ephedrine; Female; Histamine | 2005 |
Desloratadine and levocetirizine improve nasal symptoms, airflow, and allergic inflammation in patients with perennial allergic rhinitis: a pilot study.
Topics: Adolescent; Adult; Cetirizine; Double-Blind Method; Eosinophils; Female; Histamine H1 Antagonists, N | 2005 |
Effect of desloratadine therapy on symptom scores and measures of nasal patency in seasonal allergic rhinitis: results of a single-center, placebo-controlled trial.
Topics: Adult; Demography; Double-Blind Method; Female; Histamine H1 Antagonists, Non-Sedating; Humans; Lora | 2006 |
Efficacy of diphenhydramine vs desloratadine and placebo in patients with moderate-to-severe seasonal allergic rhinitis.
Topics: Adolescent; Adult; Aged; Anti-Allergic Agents; Child; Diphenhydramine; Double-Blind Method; Female; | 2006 |
Desloratadine reduces nasal congestion in patients with intermittent allergic rhinitis.
Topics: Adolescent; Adult; Aged; Child; Circadian Rhythm; Dose-Response Relationship, Drug; Double-Blind Met | 2001 |
Effect of desloratadine versus placebo on nasal airflow and subjective measures of nasal obstruction in subjects with grass pollen-induced allergic rhinitis in an allergen-exposure unit.
Topics: Adult; Cross-Over Studies; Double-Blind Method; Female; Histamine H1 Antagonists; Humans; Loratadine | 2002 |
Comparison of loratadine and terfenadine in allergic seasonal rhinoconjunctivitis with emphasis on nasal stuffiness and peak flow.
Topics: Adolescent; Adult; Aged; Conjunctivitis, Allergic; Double-Blind Method; Female; Humans; Loratadine; | 1992 |
5 other studies available for loratadine and Nasal Obstruction
| Article | Year |
|---|---|
[Modern antihistaminics against allergic rhinitis. Better breathing without side effects].
Topics: Clinical Trials as Topic; Histamine H1 Antagonists, Non-Sedating; Humans; Loratadine; Nasal Obstruct | 2003 |
[Nasal obstruction on the decline. Antihistamine allows allergic patients to breathe].
Topics: Cholinergic Antagonists; Clinical Trials as Topic; Histamine H1 Antagonists, Non-Sedating; Humans; L | 2004 |
Modern histamine H1-receptor antagonists in the unified airway.
Topics: Cetirizine; Histamine H1 Antagonists, Non-Sedating; Humans; Loratadine; Nasal Obstruction; Nasal Pro | 2004 |
[The influence of desloratadine on course of intermittens allergic rhinitis].
Topics: Adolescent; Adult; Child; Child, Preschool; Conjunctivitis, Allergic; Disease Progression; Female; H | 2005 |
[Seasonal allergic rhinitis. Nasal obstruction can also beh improved].
Topics: Anti-Allergic Agents; Double-Blind Method; Humans; Loratadine; Multicenter Studies as Topic; Nasal O | 2001 |